Zocitab
Formulated to alleviate neoplastic cellular growth to support cancer remission and target tumour cell proliferation.
- Categories
- Women's Health · Oncology Support
- Active ingredient
- Capecitabine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 500mg
Prescription and consultation requirements for Zocitab vary by destination and are determined by the fulfilment partner.
Zocitab details
- Conditions
- Metastatic Breast Cancer · Colorectal Cancer
- Alternative names
- capecitabine
- Therapeutic class
- Fluoropyrimidine Carbamate
- Pharmacological class
- Antineoplastic
- Known off-label uses
- gastric cancer
- Contraindications
- severe renal impairment; known dihydropyrimidine dehydrogenase (DPD) deficiency
- Minor side effects
- nausea; diarrhoea; vomiting
- Moderate side effects
- hand-foot syndrome; fatigue; myelosuppression
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Fresenius Kabi
- Onset Time
- 2–4 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store below 25°C. Keep dry.
- Drug interactions
- Warfarin; Phenytoin; Leucovorin
- Age restrictions
- Approved for adults.
Serious side effects
severe cardiotoxicity, requires immediate medical attention; severe diarrhoea with dehydration, requires immediate medical attention
Patient summary
formulated to alleviate neoplastic cellular growth to support cancer remission and target tumour cell proliferation.
Mechanism of action
Enzymatically converts to 5-fluorouracil in tumour cells, inhibiting thymidylate synthase to block DNA synthesis.
Pregnancy and breastfeeding
TGA Category D: High risk of fetal toxicity. Strictly contraindicated in pregnancy. Breastfeeding: Contraindicated.